Flare of hepatitis B virus after fingolimod treatment for relapsing and remitting multiple sclerosis

J Formos Med Assoc. 2020 Apr;119(4):886-887. doi: 10.1016/j.jfma.2019.10.012. Epub 2019 Oct 31.

Authors

Meng-Chuan Lu¹, Yu-Lueng Shih¹, Tsai-Yuan Hsieh¹, Jung-Chun Lin²

Affiliations

¹ Division of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
² Division of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan. Electronic address: doc10506@gmail.com.

PMID: 31679907
DOI: 10.1016/j.jfma.2019.10.012

No abstract available

Publication types

Letter
Comment

MeSH terms

Cost-Benefit Analysis
Fingolimod Hydrochloride
Hepatitis B virus
Humans
Immunosuppressive Agents
Lymphoma*
Multiple Sclerosis*
Neoplasm Recurrence, Local

Substances

Immunosuppressive Agents
Fingolimod Hydrochloride